Whitepaper: Early product characterisation mitigates risks in biologics development
Posted: 4 March 2021 | Merck | No comments yet
Product characterisation facilitates easier process design to ensure the biological drug attains critical product safety, purity, and potency.
Product characterisation is the essential foundation for successful biological drug development. In-depth knowledge of a product’s chemistry, structure, and biological activities facilitates easier process design to ensure the drug attains critical product safety, purity, and potency. Key is understanding the relationship between the basic physicochemical profile and biological activity and how this relationship affects clinical performance thus enabling a developer to make informed decisions that accelerate development and reduce risk throughout the product’s life cycle.
Related content from this organisation
- Global bioreactor market to value over $16bn by 2027
- The big debate. Beyond the data and document distinction: how to transform life sciences experiences via improved information flow
- Brochure: Integrated bioprocessing
- Moving towards the digitalisation of your lab, with the 8th edition of the Paperless Lab Academy® – this year, online
- Gilead and Merck to collaborate on long-acting HIV treatments
Related topics
Biologics, Biopharmaceuticals, Bioprocessing, Biosimilars, Chromatography, Endotoxin, Gene therapy, Good Manufacturing Practice (GMP), Ingredients, Manufacturing, Mass Spectrometry, Outsourcing, QA/QC, Regulation & Legislation, Research & Development (R&D), Vaccines
